Shares of Novo Nordisk skidded on Tuesday as the Danish drugmaker reduced its expectations on wildly popular drugs Ozempic ...

Danish pharmaceutical giant Novo Nordisk (NYSE:NVO) is watching its stock plummet 20% in morning trading after slashing its ...

Novo Nordisk slashed its financial forecasts as it struggled to fight off competition in the United States. It also named a ...

Novo Nordisk A/S (NYSE:NVO), the Danish pharmaceutical giant renowned for its weight-loss drug Wegovy and diabetes treatment ...

Compounding pharmacies are crimping sales of Novo Nordisk's obesity drug Wegovy by making what are essentially copies of the ...

Novo Nordisk’s plummet is a warning for backers who’ve crowded into a relatively small group of very large stocks.

The Danish firm blamed the move to slash its guidance on intense competition from rivals and copycat drugs in the US.

While Novo Nordisk blamed rival drugs and its own tepid expansion for downgrades to sales and profit growth, some analysts ...

Shares in the maker of Ozempic crashed to three-year low after the pharma giant warned its injections were losing ground to ...

The diabetes drugs Ozempic and Wegovy have been linked to an increased risk of sudden vision loss and blindness due to a rare ...

While Ozempic is effective at treating type 2 diabetes and supporting weight loss, it can also come with side effects.

The explosive popularity of GLP-1 weight-loss medications such as Ozempic®, Wegovy®, and Mounjaro® has transformed obesity care and created an unexpected cosmetic challenge. Rapid fat loss can leave ...